NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $131 | -70.0% | 186,265 | -3.4% | 0.00% | -100.0% |
| Q4 2022 | $436 | -99.9% | 192,793 | -0.5% | 0.00% | -50.0% |
| Q3 2022 | $620,000 | -10.8% | 193,723 | +5.9% | 0.00% | 0.0% |
| Q2 2022 | $695,000 | -14.2% | 183,006 | +21.8% | 0.00% | 0.0% |
| Q1 2022 | $810,000 | -60.1% | 150,243 | +0.0% | 0.00% | -50.0% |
| Q4 2021 | $2,029,000 | +135.1% | 150,195 | +212.6% | 0.00% | +100.0% |
| Q3 2021 | $863,000 | -15.7% | 48,043 | -19.5% | 0.00% | 0.0% |
| Q2 2021 | $1,024,000 | +5.7% | 59,679 | +23.2% | 0.00% | 0.0% |
| Q1 2021 | $969,000 | +21.4% | 48,433 | +3.1% | 0.00% | 0.0% |
| Q4 2020 | $798,000 | -22.1% | 46,969 | -24.0% | 0.00% | -33.3% |
| Q3 2020 | $1,025,000 | -66.4% | 61,799 | -53.1% | 0.00% | -66.7% |
| Q2 2020 | $3,053,000 | +33.0% | 131,790 | +2.5% | 0.01% | +12.5% |
| Q1 2020 | $2,295,000 | +131.4% | 128,589 | +179.7% | 0.01% | +166.7% |
| Q4 2019 | $992,000 | +255.6% | 45,967 | +486.0% | 0.00% | +200.0% |
| Q2 2019 | $279,000 | +6.9% | 7,844 | +1.0% | 0.00% | 0.0% |
| Q1 2019 | $261,000 | +13.0% | 7,765 | +10.3% | 0.00% | 0.0% |
| Q4 2018 | $231,000 | -45.3% | 7,042 | +1.8% | 0.00% | 0.0% |
| Q3 2018 | $422,000 | +27.9% | 6,918 | +2.3% | 0.00% | 0.0% |
| Q2 2018 | $330,000 | -53.8% | 6,765 | +0.6% | 0.00% | -50.0% |
| Q1 2018 | $714,000 | -87.8% | 6,724 | -93.1% | 0.00% | -90.0% |
| Q4 2017 | $5,832,000 | +153.8% | 97,655 | +2.0% | 0.02% | +150.0% |
| Q3 2017 | $2,298,000 | +24.9% | 95,730 | +1.7% | 0.01% | 0.0% |
| Q2 2017 | $1,840,000 | -7.4% | 94,130 | +11.2% | 0.01% | -11.1% |
| Q1 2017 | $1,987,000 | +97.1% | 84,660 | +3.1% | 0.01% | +125.0% |
| Q4 2016 | $1,008,000 | -16.6% | 82,150 | +16.7% | 0.00% | -33.3% |
| Q3 2016 | $1,209,000 | +28.3% | 70,380 | +6.3% | 0.01% | +50.0% |
| Q2 2016 | $942,000 | +12.4% | 66,180 | +8.6% | 0.00% | 0.0% |
| Q1 2016 | $838,000 | -12.1% | 60,950 | +7.7% | 0.00% | -20.0% |
| Q4 2015 | $953,000 | +58.0% | 56,580 | +2.8% | 0.01% | +66.7% |
| Q3 2015 | $603,000 | -3.7% | 55,050 | +10.1% | 0.00% | 0.0% |
| Q2 2015 | $626,000 | – | 50,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |